Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MPH313
Etigilimab · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Etigilimab | DRUG | IV infusion of IV etigilimab every 2 weeks |
| Nivolumab | DRUG | IV infusion of nivolumab every 2 weeks |
Etigilimab is an investigational monoclonal antibody being studied for the treatment of locally advanced or metastatic solid tumors in adults. It is not approved for any indication and remains in clinical development. The only completed trial evaluated it in combination with nivolumab in participants with advanced or metastatic solid tumors.
Etigilimab targets TIGIT, an inhibitory receptor expressed on immune cells. As a TIGIT inhibitor, it is designed to block this checkpoint and may enhance antitumor immune responses. The target class is inhibitor, and the mechanism is intended to support immune-mediated attack on tumor cells.
Etigilimab is being developed by Mereo BioPharma Group plc, which trades on the Nasdaq under the ticker MREO. The company is responsible for the clinical program evaluating the drug in solid tumors.
Etigilimab is in Phase 2 clinical development. The single completed trial was a Phase 1/Phase 2 study, and the drug has not been approved by the FDA or any regulatory agency. It remains an investigational agent for advanced solid tumors.
Etigilimab has been evaluated in one completed clinical trial, NCT04761198, titled A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors. This Phase 1/Phase 2 trial enrolled 76 participants and is now completed. No active trials are currently listed.